Home > Insider Trading > Filing (0000880771-16-000175)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
880771	Sciclone Pharmaceuticals Inc	SCLN	Pharmaceutical Preparations (2834)	943116852

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1635264	Robert King	950 Tower Lane, Suite 900 Foster City CA 94404	Svp Of Prod. Dev/Supply Chain	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2016-08-12	46,667	$4.52	63,511	No	4	M	Direct
Common Stock	Disposition	2016-08-12	46,667	$10.41	16,844	No	4	S	Direct
Common Stock	Acquisiton	2016-08-12	2,000	$0.00	18,844	No	4	M	Direct
Common Stock	Disposition	2016-08-12	2,000	$10.41	16,844	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Options (right to buy)	Disposition	2016-08-12	46,667	$0.00	46,667	$4.52
Common Stock	Restricted Stock Unit	Acquisiton	2016-08-12	2,000	$0.00	2,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
33,333		2024-03-14	No	4	M	Direct
13,000			No	4	M	Direct

Footnotes

Includes 4,262 shares purchased under the Issuer's Employee Stock Purchase Plan from February 28, 2015 through May 31, 2016.
Granted under the Issuer's 2005 Equity Incentive Plan.
25% of such shares vest from one year from the date of grant and 2.0833% vests each month thereafter, provided that the Reporting Person continues to be employed by the Issuer.
Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock.
Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.